Literature DB >> 17101674

Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

Eisuke Murakami1, Haiying Bao, Mangala Ramesh, Tamara R McBrayer, Tony Whitaker, Holly M Micolochick Steuer, Raymond F Schinazi, Lieven J Stuyver, Aleksandr Obikhod, Michael J Otto, Phillip A Furman.   

Abstract

Beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent specific inhibitor of hepatitis C virus (HCV) RNA synthesis in Huh-7 replicon cells. To inhibit the HCV NS5B RNA polymerase, PSI-6130 must be phosphorylated to the 5'-triphosphate form. The phosphorylation of PSI-6130 and inhibition of HCV NS5B were investigated. The phosphorylation of PSI-6130 by recombinant human 2'-deoxycytidine kinase (dCK) and uridine-cytidine kinase 1 (UCK-1) was measured by using a coupled spectrophotometric reaction. PSI-6130 was shown to be a substrate for purified dCK, with a Km of 81 microM and a kcat of 0.007 s-1, but was not a substrate for UCK-1. PSI-6130 monophosphate (PSI-6130-MP) was efficiently phosphorylated to the diphosphate and subsequently to the triphosphate by recombinant human UMP-CMP kinase and nucleoside diphosphate kinase, respectively. The inhibition of wild-type and mutated (S282T) HCV NS5B RNA polymerases was studied. The steady-state inhibition constant (Ki) for PSI-6130 triphosphate (PSI-6130-TP) with the wild-type enzyme was 4.3 microM. Similar results were obtained with 2'-C-methyladenosine triphosphate (Ki=1.5 microM) and 2'-C-methylcytidine triphosphate (Ki=1.6 microM). NS5B with the S282T mutation, which is known to confer resistance to 2'-C-methyladenosine, was inhibited by PSI-6130-TP as efficiently as the wild type. Incorporation of PSI-6130-MP into RNA catalyzed by purified NS5B RNA polymerase resulted in chain termination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101674      PMCID: PMC1797721          DOI: 10.1128/AAC.00400-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Unravelling hepatitis C virus replication from genome to function.

Authors:  Brett D Lindenbach; Charles M Rice
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

2.  Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases.

Authors:  A R Van Rompay; A Norda; K Lindén; M Johansson; A Karlsson
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Jeremy Clark; Laurent Hollecker; Stefania Lostia; Tammy Nachman; Jason Grier; Matthew A Bennett; Meng-Yu Xie; Raymond F Schinazi; John D Morrey; Justin L Julander; Phillip A Furman; Michael J Otto
Journal:  Antivir Chem Chemother       Date:  2006

Review 4.  Antiviral drug discovery and development: where chemistry meets with biomedicine.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2005-08       Impact factor: 5.970

5.  Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium.

Authors:  Chih-Hung Hsu; Jieh-Yuan Liou; Ginger E Dutschman; Yung-Chi Cheng
Journal:  Mol Pharmacol       Date:  2004-11-18       Impact factor: 4.436

Review 6.  Challenges and successes in developing new therapies for hepatitis C.

Authors:  Raffaele De Francesco; Giovanni Migliaccio
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

7.  Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.

Authors:  Jeremy L Clark; Laurent Hollecker; J Christian Mason; Lieven J Stuyver; Phillip M Tharnish; Stefania Lostia; Tamara R McBrayer; Raymond F Schinazi; Kyoichi A Watanabe; Michael J Otto; Phillip A Furman; Wojciech J Stec; Steven E Patterson; Krzysztof W Pankiewicz
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

8.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

9.  A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase.

Authors:  Z Hong; C E Cameron; M P Walker; C Castro; N Yao; J Y Lau; W Zhong
Journal:  Virology       Date:  2001-06-20       Impact factor: 3.616

10.  HCV RNA-dependent RNA polymerase replicates in vitro the 3' terminal region of the minus-strand viral RNA more efficiently than the 3' terminal region of the plus RNA.

Authors:  S Reigadas; M Ventura; L Sarih-Cottin; M Castroviejo; S Litvak; T Astier-Gin
Journal:  Eur J Biochem       Date:  2001-11
View more
  31 in total

Review 1.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

Review 2.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

3.  Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.

Authors:  Angela M Lam; Christine Espiritu; Eisuke Murakami; Veronique Zennou; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Nigel Bourne; Ronald L Veselenak; P Ganapati Reddy; Wonsuk Chang; Jinfa Du; Dhanapalan Nagarathnam; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

4.  Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.

Authors:  Ya-Chi Chen; Coen Bernaards; Rohit Kulkarni; Sebastian Moreira; Yonghong Zhu; Anna Chan; Ethan Badman; Andrew Ackrill; James Thommes; Patrick F Smith
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  Concentration of 2'C-methyladenosine triphosphate by Leishmania guyanensis enables specific inhibition of Leishmania RNA virus 1 via its RNA polymerase.

Authors:  John I Robinson; Stephen M Beverley
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

6.  Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.

Authors:  Justin G Julander; Ashok K Jha; Jung-Ae Choi; Kie-Hoon Jung; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

7.  The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Eisuke Murakami; Congrong Niu; Haiying Bao; Holly M Micolochick Steuer; Tony Whitaker; Tammy Nachman; Michael A Sofia; Peiyuan Wang; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

8.  Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Authors:  Hyo-Joong Kim; Ashoke Sharon; Chandralata Bal; Jianing Wang; Madhan Allu; Zhuhui Huang; Michael G Murray; Leda Bassit; Raymond F Schinazi; Brent Korba; Chung K Chu
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

9.  Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.

Authors:  Leda Bassit; Jason Grier; Matthew Bennett; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2008

10.  Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Junxing Shi; Brenda I Hernandez-Santiago; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.